1. Home
  2. MYGN

MYGN

Myriad Genetics Inc.

Logo Myriad Genetics Inc.

Health Care

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Nasdaq

as 04-22-2024 10:31am EST

$
-
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

Founded: 1991 Country:
United States
United States
Employees: 2700 City: SALT LAKE CITY
Market Cap: 1.7B IPO Year: 1995
Target Price: $22.50 AVG Volume (30 days): 620.4K
Analyst Decision: Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.18 EPS Growth: N/A
52 Week Low/High: $13.82 - $24.21 Next Earning Date: 05-01-2024
Revenue: $753,200,000 Revenue Growth: 11.03%
Revenue Growth (this year): 11.95% Revenue Growth (next year): 8.24%

Share on Social Networks:

Stock Insider Trading Activity of Myriad Genetics Inc. (MYGN)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Riggsbee Richard Bryan MYGN Chief Financial Officer Dec 1 '23 Sell $19.09 30,000 $572,835.00 291,812 SEC Form 4